Managing Partners

Guy Geldhof

Guy Geldhof

  • CFO Vesalius Biocapital Fund 1
  • Partner Fund 2 and Managing Partner Fund 3

Guy Geldhof has over 24 years of relevant experience, i.a. since 2008 as CFO, Partner and Managing Partner of Vesalius Biocapital and as Co-Founder of Value4Growth (a specialized consulting and management firm to support life science companies together with Stéphane Verdood and Gaston Matthyssens).

Guy was a member of the business advisory and audit team at Arthur Andersen in Houston and, later, in Brussels He also held the position of Secretary General of the BVA, the Belgian Venture Capital and Private Equity Association. Guy Geldhof has a Master's degree in commercial engineering from the Free University of Brussels.


Marc Lohrmann

Marc Lohrmann

  • Managing Partner Vesalius Biocapital Fund 3

Marc Lohrmann has over 18 years of experience and joined Vesalius Biocapital in 2012 as a venture partner. Since then, Marc advised on corporate development and exit of portfolio companies of Fund 1 and Fund 2. He was promoted to Managing Partner for Fund 3 in 2017.

Marc started eight lifesciences companies, i.a. co-founded Reverse Medical (acquired by Covidien in 2014) and Softhale (acquired by Sino Biopharm in 2021), was an investment manager at Bayer Innovation and worked with several corporate finance boutiques focused on life sciences M&A transactions. Marc holds a diploma degree in business administration of the University of Stuttgart-Hohenheim (Germany).


Chrisitian Schneider

Dr. Christian Schneider

  • Managing Partner Vesalius Biocapital Fund 1, Fund 2 and Fund 3

Dr. Christian Schneider has over 24 years of relevant experience in life sciences. He is Managing Partner of Vesalius Biocapital Fund 1, Fund 2 and Fund 3 and Lead Partner for Activaero (acquired by Vectura Group), Humedics, Omeicos, Ventaleon and Softhale.

He joined venture capital firm PolyTechnos in 2001 and was responsible for investments in i.a. OncoMethylome Sciences, Devgen and Jerini. During his professional career, he worked at Boehringer Mannheim / Roche and Centocor / Johnson&Johnson. Christian holds a doctorate degree in veterinary medicine (1992) and a PhD in immunology (1995), both from the University of Munich, Germany, and a MBA from Penn State University, Pennsylvania (1999).


Stephane Verdood

Stéphane Verdood

  • Managing Partner Vesalius Biocapital Fund 1, Fund 2 and Fund 3

Stéphane Verdood has over 26 years of experience in the life sciences industry. He is Managing Partner of Vesalius Biocapital Fund 1, Fund 2 and Fund 3 and Lead Partner for Apitope, FF Pharma, Genkyotex (reverse merger with Genticel, now Euronext-quoted), Genomic Vision (Euronext-quoted) and Trod Medical.

Stéphane was Founder and Managing Partner at Value4Growth, a specialized Life Science consulting firm, together with Gaston Matthyssens and Guy Geldhof. He i.a. founded and led Arthur Andersen's business consulting division in Belgium and Luxembourg and served on the European Board of Partners of Arthur Andersen. Stéphane has a MBA and a Master's degree in commercial engineering from the Catholic University of Leuven.

Extended Operational Team

Virginie Michielsen

Virginie Michielsen

Virginie Michielsen joined Vesalius Biocapital Fund III in January 2020 as a Conducting Officer, based in Luxembourg. She has an extensive financial background in the banking sector of more than 25 years. From 1986 to 2013 she worked for BBL (Bank Brussels Lambert) which later merged with ING. She had various key functions in the Corporate Banking department (SMEs and Corporates), the Trade and Commodities finance and Financial Institutions in Brussels and Amsterdam. In 2013 Virginie became Head of Marketing and Communication department at Deloitte Luxemburg and since 2018 she is part time Senior Business Developer at FEDIL, the business federation for Industry in Luxembourg. As an independent consultant she has several projects in various domains using her strong organizational, communication and banking background.

Virginie studied Applied Economics, specialization in Financial and General Management, cum laude, in Antwerp. She has a post university degree in European History, Politics and Law from the I.H.E.E. (Institut des Hautes Etudes Européennes) in Strasbourg (F).


David Braga-Malta

Dr. David Braga Malta

  • Venture Partner Vesalius Biocapital Fund 3

Dr. David Braga Malta is a Life Sciences Entrepreneur, Inventor and Investor, i.a. founded Cell2B and BoostPharma, where he served as president and director respectively, as well as LiMM Therapeutics, where he is acting CEO.


He joined Vesalius Biocapital Fund 3 as Venture Partner domiciled in Lisbon and Paris. Before that, David was Venture Consultant for Caixa Capital, helping to establish a Life Sciences investment policy for Portugal. He was nominated a World Economic Forum Global Shaper, being currently the curator of the Lisbon Hub. David holds a PhD in Bioengineering from the MIT Portugal Program and a M.Sc. Degree in Biological Engineering, Instituto Superior Técnico, Portugal.


Fabienne Roussell

Dr. Fabienne Roussel

  • Analyst Vesalius Biocapital Fund 3

Dr. Fabienne Roussel joined Vesalius Biocapital as an analyst in 2016. She was i.a. working at Pfizer Central Research in the US, became a patent agent while working at a private law firm in Houston and a biotechnology company in Rockville.

Fabienne is a Registered Technology Transfer Professional (RTTP) and has been working as a technology transfer specialist ever since. She obtained her Ph.D. in Pharmaco-Toxicology from the Université Paris VII – Denis Diderot (1995)


Fei Thian

Dr. Fei Tian

  • Analyst Vesalius Biocapital Fund 1 and Fund 2
  • Principal Fund 3

Dr. Fei Tian joined Vesalius Biocapital as an Analyst in 2012and was promoted to Principal in 2017. She holds a M.D. (Medical Doctor) degree (2008) from Shanghai Tongji University, People's Republic of China.

Fei began her career as a physician in emergency medicine and pursued her interest in pulmonary oncology research for her scientific doctoral degree for a PhD at the Ludwig-Maximilian University and Thoracic Oncology Center, Munich, Germany.


Wortel Cees

Dr. Cees Wortel

  • Venture Partner Vesalius Biocapital Fund 3

Dr. Cees Wortel joined Vesalius Biocapital Fund 3 as a Venture Partner domiciled in Boston. He i.a. founded Clinquest in 1998, an entrepreneurial CRO with operations in Europe and the US; the company was acquired by Accelovance in 2015.

Cees has served as a senior medical research executive for several biopharmaceutical companies, including Centocor, Inc., Repligen Inc., Procept Inc. and Alkermes, Inc. While at Centocor he was engaged in the first biological (Remicade®) program. He has served as (acting) CMO for many CRO client companies. He has received his medical training at the University of Amsterdam, and received his PhD in Immunology in 1993.

Support Team

Martine Gossens

Martine Goossens

  • Management Assistant



Martine Goossens joined Vesalius Biocapital in 2012. Before that, she worked for multinational companies (BNP Paribas Fortis, Kuwait Petroleum) as well as for SMEs (Belven, Avia Brouw). Martine studied Germanic Philology at the University of Leuven and has a bachelor degree in SME-Management.


Judith Murazishya

Judith Murazishya

  • Management Assistant



Judith Murazishya joined Vesalius Biocapital in 2009. Before, she worked for non-profit organisations, where she got her first professional experience in Europe. Judith graduated from High School in Rwanda and became primary and high school teacher.


Pauki Tran

Pauki Tran

  • Controller



Pauki Tran joined Vesalius Biocapital in 2012 as a Controller. She previously worked in budget management at CNRS in France and at Group ARaymond, including a four years tenure in Shenzhen (China). Pauki Tran has a Master degree in business management at University Creteil (France).